Loading clinical trials...

RECRUITINGPHASE2/PHASE3

Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

Treatment of Primary CNS Lymphoma With Systemic R-IDARAM Chemotherapy and Intrathecal Immunochemotherapy

NCT02657785•Navy General Hospital, Beijing

Summary

This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in primary central nervous system lymphoma (PCNSL) patients.

Detailed Description

The investigators will evaluate response rate, progression free survival (PFS), overall survival (OS), and toxicity in primary central nervous system lymphoma (PCNSL) after systemic and intrathecal immunochemotherapy with deferred radiotherapy.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).

Exclusion Criteria

•Involved sites other than the brain, meninges, CSF, or the eyes.
•Age less than 18 years or greater than 75 years.
•Inadequate bone marrow capacity (defined as neutrophils\<1.5 ×10\^9/L, platelets \<100 ×10\^9/L, and hemoglobin level\< 8 g/dL).
•Known cause of immunosuppression (ie, HIV type I infection).
•Any previous malignancy.
•Creatinine clearance below 60 mL/min.
•Heart insufficiency (NYHA IIIB or IV).
•Uncontrolled infection.
•Noncompensated active pulmonary or liver disease.
•Previously treated for PCNSL, except by corticosteroids.

Locations (1)

Navy General Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

September 1, 2010

Primary Completion Date

December 1, 2028

Completion Date

December 1, 2030

Last Updated

September 9, 2020

Enrollment

100

ESTIMATED participants

Conditions

Primary Central Nervous System Lymphoma

Interventions

R-IDARAM plus intrathecal chemotherapy

DRUG

Contacts

Liren Qian, M.D.

CONTACT

+861066957676 qlr2007@126.com

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

NCT02203526

Primary Central Nervous System Lymphoma

View study

RECRUITINGPHASE1/PHASE2

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

NCT03328078

Relapsed Hematologic MalignancyRefractory Hematologic Malignancy+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 9, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy

Inclusion Criteria

Exclusion Criteria

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL

Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients

Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL